Halofuginone hydrobromide

Overview

Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K i of 18.3 nM. Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels . Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hypertension | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Parasite | Products > Signaling Pathways > Sodium Channel | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > TGF-beta/Smad

Product Information

• Catalog No.: HY-N1584A
• CAS No.: 64924-67-0
• Molecular Formula: C16H18Br2ClN3O3
• Molecular Weight: 495.59
• Purity: 99.85%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (5.04 mM); Clear solution
• Availability: In-stock

Source

Original product source